Cannabis Science Provides Updated Guidance on its Current Pre-Clinical Drug Development Programs Beginning with the Scientific Cannabis Cultivation Programs in Europe and North America, Testing Multiple Cannabis Strains for Multiple Critical Ailments Pre-Clinical Drug Development Targeting Potential Medicinal Applications Starting with Cancer and Neurological Disorders Being Investigated with Progress Report
COLORADO SPRINGS, Colo., Aug. 26, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to provide a guidance report on its current pre-clinical drug development programs underway, beginning with the scientific cannabis cultivation programs in Europe and North America, testing multiple cannabis strains for multiple critical ailments.
Mr. Mario S. Lap, Director and President of European Operations, stated, " The Company's efforts in Spain compliment Cannabis Science's plans in Canada and the Company's current, pre-clinical collaboration with the Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy, where the Company is testing toxicity and efficacy of cannabinoid formulations for neurobehavioral diseases including sleep disorders."
The facilities are located in the Alicante region of Spain; the Company has successfully initiated an agricultural program spanning combined 15 hectares parceled according to seed strains and growth cycles and protocols. Focused on GMP production requirements and research framework to conduct scientific testing of the active constituents contained in the cannabis plant. The company will set these protocols to multiply optimal results into drug formulation regiments for pre-clinical studies.
The current progress is based on multiple harvests processed thus far and proprietary harvest process and successful transitions into extracts for multiple targeted drug development. The Company has now received data on three harvests for hemp and expecting its cannabis results shortly. This data is critical in the initial stages of our drug development programs as it can be replicated on an international basis for multiple jurisdictional drug development programs.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
Raymond C. Dabney, Management Consultant, Co-Founder
SOURCE Cannabis Science, Inc.